Intravenous XXXX injection test is a novel complementary procedure in differential diagnosis for @entity7581 .

@entity1 @entity8703 @entity5 @entity11384 @entity8579 @entity8243 @entity460 @entity7581
The current study evaluated efficacy of the intravenous @entity460 injection test as a new diagnostic approach to clarify the existence of @entity7581 , which often goes undetected with routine testing. Twenty-six @entity1 with hypergastrinemia were studied. For the @entity460 injection test, blood samples were taken from 12 @entity1 with hypergastrinemia (HG), and three healthy volunteers, and one @entity1 with nonfunctioning @entity8703 in the pancreas (control). We compared results of the @entity460 injection test with those of the secretin test and the selective arterial secretagogue injection (SASI) test. The SASI test with @entity11384 was performed in 24 of 26 @entity1 with hypergastrinemia, including 22 of 24 @entity1 with @entity8579 ( @entity8579 ). Accuracy in the diagnosis of @entity5 localization by the SASI test was 95% (21 of 22) in @entity8579 @entity1 . The secretin test was negative in 3 of 21 @entity1 with @entity8579 (14%). Either the secretin test or the SASI test was positive in 22 of 23 @entity1 (96%). The @entity460 injection test was administered to 12 @entity1 in the HG group and 4 controls. The HG group showed significantly higher serum @entity8243 levels than those of the control group in the @entity460 injection test. Eight of 10 @entity8579 @entity1 (80%) had a positive @entity460 injection test. We could diagnose @entity7581 in 100% of @entity8579 @entity1 by either the @entity460 injection test or the secretin test. We have thus confirmed the efficacy of the intravenous @entity460 injection test in the diagnosis of @entity7581 . The @entity460 injection test could become an adjunct in the diagnosis of @entity7581 , which often goes undetected with routine testing.
